Reduction of the activity of the KCNQ4 channel has been associated with a genetic form of hearing loss, noise-induced hearing loss, and age-related hearing loss [6,7,8]; therefore, small compounds that activate KCNQ4, the so-called “channel openers”, have been developed as a strategy for the treatment of these hearing impairments [9]. The gene discussed is KCNQ4; the disease is Hearing impairment.